Metformin targets c-MYC oncogene to prevent prostate cancer.

  title={Metformin targets c-MYC oncogene to prevent prostate cancer.},
  author={Tunde Akinyeke and Satoko Matsumura and Xinying Wang and Yingjie Wu and Eric D Schalfer and Anjana Saxena and Wenbo Yan and Susan K Logan and Xin Li},
  volume={34 12},
UNLABELLED Prostate cancer (PCa) is the second leading cause of cancer-related death in American men and many PCa patients develop skeletal metastasis. Current treatment modalities for metastatic PCa are mostly palliative with poor prognosis. Epidemiological studies indicated that patients receiving the diabetic drug metformin have lower PCa risk and better prognosis, suggesting that metformin may have antineoplastic effects. The mechanism by which metformin acts as chemopreventive agent to… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 46 extracted citations


Publications referenced by this paper.
Showing 1-10 of 47 references

A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy

  • Nobes, J.P
  • BJU Int
  • 2011

Inhibitory effects of megakaryocytic cells in prostate cancer skeletal metastasis

  • X Li
  • J. Bone Miner. Res.,
  • 2011

Similar Papers

Loading similar papers…